Logo Prima Biomed

Welcome to the Newsroom

13 October 2015

Prima BioMed raises A$1.55M through Placement to Sophisticated European Healthcare Investor


SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, announces that it has raised €1M (approx. A$1.55M) via a placement of shares at A$0.05 per share (Placement) to Nyenburgh Investment Partners (NYIP).

Nyenburgh Investment Partners (NYIP), based in the Netherlands, is a specialist healthcare investor. Founded by Alexander Jordaan, Dave van Mastwijk and Ivar van der Salm, NYIP takes long term positions in life sciences companies globally with a specific focus on biotechnology. Further information on NYIP can be found at http://www.nyip.nl.

The proceeds from the Placement will be used to fund Prima’s IMP321 clinical trial program and provide additional working capital.